Search

Your search keyword '"Vitamin D-Binding Protein chemistry"' showing total 3 results
Start Over Descriptor "Vitamin D-Binding Protein chemistry" Topic neoplasms
3 results on '"Vitamin D-Binding Protein chemistry"'

1. Oleic Acid, deglycosylated vitamin D-binding protein, nitric oxide: a molecular triad made lethal to cancer.

Author

Ruggiero M, Ward E, Smith R, Branca JJ, Noakes D, Morucci G, Taubmann M, Thyer L, and Pacini S

Subjects
Aspirin administration & dosage, Cholecalciferol administration & dosage, Combined Modality Therapy, Dietary Carbohydrates administration & dosage, Dietary Proteins administration & dosage, Drug Synergism, Female, Humans, Immunotherapy, Macrophage-Activating Factors chemistry, Macrophages drug effects, Macrophages metabolism, Male, Middle Aged, Neoplasms diet therapy, Neoplasms drug therapy, Neoplasms metabolism, Oleic Acid chemistry, Vitamin D-Binding Protein chemistry, Macrophage-Activating Factors administration & dosage, Neoplasms therapy, Nitric Oxide metabolism, Oleic Acid administration & dosage, Vitamin D-Binding Protein administration & dosage
Abstract

Background: Oleic Acid (OA) has been shown to have anticancer properties mediated by interaction with proteins such as α-lactalbumin and lactoferrins. Therefore, we synthesized complexes of OA and Gc protein-derived macrophage activating factor (GcMAF) that inhibits per se cancer cell proliferation and metastatic potential. We hypothesised that OA-GcMAF complexes could exploit the anticancer properties of both OA and GcMAF in a synergistic manner. We postulated that the stimulating effects of GcMAF on macrophages might lead to release of nitric oxide (NO)., Patients and Methods: Patients with advanced cancer were treated at the Immuno Biotech Treatment Centre with OA-GcMAF-based integrative immunotherapy in combination with a low-carbohydrate, high-protein diet, fermented milk products containing naturally-produced GcMAF, Vitamin D3, omega-3 fatty acids and low-dose acetylsalicylic acid., Results: Measuring the tumour by ultrasonographic techniques, we observed a decrease of tumour volume of about 25%., Conclusion: These observations demonstrate that OA, GcMAF and NO can be properly combined and specifically delivered to advanced cancer patients with significant effects on immune system stimulation and tumour volume reduction avoiding harmful side-effects., (Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2014

2. Glycosylation status of vitamin D binding protein in cancer patients.

Author

Rehder DS, Nelson RW, and Borges CR

Subjects
Female, Glycosylation, Humans, Immunoassay, Macrophage-Activating Factors blood, Macrophage-Activating Factors metabolism, Male, Neoplasms blood, Spectrometry, Mass, Electrospray Ionization, Trisaccharides chemistry, Vitamin D-Binding Protein blood, Vitamin D-Binding Protein chemistry, Neoplasms metabolism, Trisaccharides metabolism, Vitamin D-Binding Protein metabolism
Abstract

On the basis of the results of activity studies, previous reports have suggested that vitamin D binding protein (DBP) is significantly or even completely deglycosylated in cancer patients, eliminating the molecular precursor of the immunologically important Gc macrophage activating factor (GcMAF), a glycosidase-derived product of DBP. The purpose of this investigation was to directly determine the relative degree of O-linked trisaccharide glycosylation of serum-derived DBP in human breast, colorectal, pancreatic, and prostate cancer patients. Results obtained by electrospray ionization-based mass spectrometric immunoassay showed that there was no significant depletion of DBP trisaccharide glycosylation in the 56 cancer patients examined relative to healthy controls. These results suggest that alternative hypotheses regarding the molecular and/or structural origins of GcMAF must be considered to explain the relative inability of cancer patient serum to activate macrophages.

Published
2009
Full Text
View/download PDF

3. Therapeutic potential of vitamin D-binding protein.

Author

Gomme PT and Bertolini J

Subjects
Actins metabolism, Animals, Anti-Inflammatory Agents therapeutic use, Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Humans, Immunologic Factors therapeutic use, Macrophage Activation drug effects, Macrophage Activation immunology, Macrophages metabolism, Protein Binding, Vitamin D-Binding Protein chemistry, Vitamin D-Binding Protein immunology, Inflammation drug therapy, Neoplasms drug therapy, Osteopetrosis drug therapy, Pulmonary Disease, Chronic Obstructive drug therapy, Vitamin D-Binding Protein metabolism, Vitamin D-Binding Protein therapeutic use
Abstract

Vitamin D-binding protein (DBP) is a multi-functional plasma protein with many important functions. These include transport of vitamin D metabolites, control of bone development, binding of fatty acids, sequestration of actin and a range of less-defined roles in modulating immune and inflammatory responses. Exploitation of the unique properties of DBP could enable the development of important therapeutic agents for the treatment of a variety of diseases.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results